First Manhattan’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History

First Manhattan’s Portfolio OXFD Stock Details OXFD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-352,500	Closed	-$3.17M	–	1490
2016 Q2	$3.17M	Sell	352,500 -13,493	-4%	-$132K	0.02%	291
2016 Q1	$3.63M	Sell	365,993 -8,700	-2%	-$89.2K	0.02%	272
2015 Q4	$4.31M	Sell	374,693 -15,907	-4%	-$197K	0.03%	253
2015 Q3	$5.27M	Hold	390,600	–	–	0.03%	226
2015 Q2	$5.41M	Sell	390,600 -9,400	-2%	-$127K	0.03%	241
2015 Q1	$5.63M	Buy	+400,000	New	+$5.44M	0.03%	239

Other funds holding OXFD

Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

GPGA

Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

First Manhattan's OXFD Position: Q3 2016 in Review

First Manhattan sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q3 2016, closing a stake of 352,500 shares — an estimated $3.17M sold.

First Manhattan first reported a position in OXFD in Q1 2015 and held it in 6 quarters. The position peaked at $5.63M in Q1 2015. 62 funds tracked by Wall St. Rank hold OXFD as of Q3 2016.

First Manhattan reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q3 2016 after selling out during the quarter.
First Manhattan sold 352,500 Oxford Immunotec Global PLC Ordinary Shares shares in Q3 2016, an estimated $3.17M.
First Manhattan first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q1 2015 and held it in 6 quarters.
First Manhattan's Oxford Immunotec Global PLC Ordinary Shares position peaked at $5.63M in Q1 2015.
62 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q3 2016.

Based on First Manhattan's 13F filing for Q3 2016, filed 20 Oct 2016.